NutropinAq

Phase 2Small molecule

Ipsen

NutropinAq is one of 19 small molecule programs targeting Short stature. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short StatureActive, not recruiting

Short StaturePhase 2

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Short Stature

#DrugCompanyPhaseTrials

Growth Hormone

Pfizer

Phase 3

2 2

Leuprorelin

Takeda

Phase 3

1 3

Saizen

Merck & Co.

Phase 3

1 4

Aromatase Inhibitor

Pfizer

Phase 3

1 5

Genotropin

Pfizer

Phase 3

1 6

Voxzogo

BioMarin Pharmaceutical

Phase 2

2 7

Genotropin

EMD Serono

Phase 2

4 8

GH Treatment (genotropin)

RRabin Medical Center

Approved

1 9

Rhgh

XXiamen Amoytop Biotech Co., Ltd.

Phase 2

1 10

Increlex

EEsteve Pharmaceuticals, S.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Short stature1 trial

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Terminated· Ipsen logo

Ipsen·Phase 2·NCT00572156·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NutropinAq. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NutropinAq compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NutropinAq. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Ipsen

NutropinAq

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Short stature1 trial

References

Drug Info

Quick Facts

Related News